A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.Evan Rosenbaum, Sandra P. D’Angelo, Mary Louise Keohan et al.|Journal of Clinical Oncology|2021Cited by 12
A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).Evan Rosenbaum, Sandra P. D’Angelo, Li‐Xuan Qin et al.|Journal of Clinical Oncology|2022Cited by 6